Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Leukemia 2Vomiting 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdoid Tumor 1Recurrence 1PRETEXT I Hepatoblastoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nausea 1Lymphoma, Large-Cell, Anaplastic 1Localized Extraskeletal Ewing Sarcoma 1Liposarcoma 1Leiomyosarcoma 1Hypersensitivity 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Ganglioneuroblastoma 1Fibrosarcoma 1Extravasations of Anthracycline Anti-cancer Agents 1Drug-Related Side Effects and Adverse Reactions 1Dermatofibrosarcoma 1Degradation of Top2b and Top2a in Human by Dexrazoxane 1Central Nervous System Neoplasms 1

Interventions

Doxorubicin 4pazopanib 2Ifosfamide 2saracatinib 1sapanisertib 1indolepropanol phosphate 1Watchful Waiting 1TTI-621 1Sunitinib 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Polymerase Chain Reaction 1Observation 1Neoadjuvant Therapy 1MLN 8237 1Imatinib Mesylate 1HhAntag691 1Gene Expression Profiling 1Dexrazoxane 1Blotting, Western 1Albumin-Bound Paclitaxel 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Dermatofibrosarcoma × Dexrazoxane × Clear all
NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 2 Completed
73 enrolled 11 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡